Document Page: First | Prev | Next | All | Image | This Release | Search
File: 092396_may96_decls1_0001.txt
Subject: ANTHRAX
Box ID: BX001429
Document Number: 3
Folder Title: MEDICAL INFORMATION ANTHRAX AND MEDEVAC PROCEDURES
Folder Seq #: 408
Unit: 24TH ID
Parent Organzation: XVIII CORPS
LIN
1. Purpose. To provide information on the medical aspects of
anthrax.
2. Facts.
a. Anthrax is caused by a spore forming bacteria %.,bich normally
affects animals primarily cattle. Under natural renditions,
man becomes Infected by contact with Infected animals.
Potential sites of disease occur In the skin, gastrointestinal
system and the lungs. The skin and Intestinal forms are more
common and easily treated.
b. Used as a biological weapon. anthrax resul.ts In pulmonary
disease, a rare form which is transmitted via inhalation of
the spores. The means of delivery is acrosoli7-ation via
spraying or munition. Once inhaled the onset of symptoms
vari@- from I - 5 days and includes fever, weakness and a non-
productive cough. This Is followed by a recovery phase of 2 -
4 days. Subsequently. severe respiratory problems develop
leading to death in cost cases. The spores are very
persistent and can remain in the soil Indefinitely despite
high temperatures.
c. The protective mask provides complete protection against the
Inhalation of anthrax spores. A vaccine Is aval@le In
limited quantities but la not currently scheduled for
administration to 24th ID (M) soldiers. Prophylaxis
(pre-treatment) with antibiotic ciprofloxecin Is effective and
thus it will be Issued to all 24th ID soldiers through medical
channels. The unit of issue Is 10 tablets per soldier (5 day
Supply. 2 tablets per day). Based upon the threat level, each
f 10 tablets. The
antibiotic doxycycline (100 mg twice a day) Is an alternative
In patients allergic to ciprofloxacin.
d. Recognition of the employment of biological weapons Is
difficult. Currently, there are no mechanical rapid detection
systems. The use of biological weapons should be suspected
when any of the following are observed: munltlon producing
cloud or mist, large numbers of deceased livestock, and an
unusual incidence of flu - like symptors or pneumonia in
personnel.
e. Upon high probability or confirmation of exwsure to a
biological weapon agent initiation of use of ciprofloxaciii
will be determined by command. The dosing schedule will bc- I
tablet twice a day. Furthermore. if anthrax exposure Is
confirmed, c4profloxaciii will be continued for, 30 days as I
tablet twice a day. In addition, exposed unvacciiiated
personnel will begin and co:.iplete the 2 shot anthrax vaccine
series during the 30 day course of antibiotics. Sufficient
quantities of ciprofloxacin for prophylaxis are available In
the Division. Quantities of vaccine and ciprofloxacin for
post - exposure treatment are being stockpiled in theater.
J. BenJamin HALI./Division Surgeon
9-7662-144
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 1 f:/Week-22/BX001429/MEDICAL INFORMATION ANTHRAX AND MEDEVAC PROCEDURES/anthrax:09069614060613
Control Fields 17
File Room = may96_declassified
File Cabinet = Week-22
Box ID = BX001429
Unit = 24TH ID
Parent Organization = XVIII CORPS
Folder Title = MEDICAL INFORMATION ANTHRAX AND MEDEVAC PROCEDURES
Folder Seq # = 408
Subject = ANTHRAX
Document Seq # = 13
Document Date =
Scan Date = 03-JUN-1996
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 06-SEP-1996